Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma

Abstract

Background:We retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients.Methods:Data were pooled from 1059 patients in six trials. Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS) were compared by log-rank test between patients aged <70 (n=857; 81%) and ⩾70 (n=202; 19%) years.Results:In first-line patients, median PFS was comparable in younger and older patients, 9.9 vs 11.0 months, respectively (HR, 0.89; 95% CI: 0.73–1.09; P=0.2629), as was median OS, 23.6 vs 25.6 months (HR, 0.93; 95% CI: 0.74–1.18; P=0.5442). Similarly, in cytokine-refractory patients, median PFS was 8.1 vs 8.4 months (HR, 0.79; 95% CI: 0.49–1.28; P=0.3350), while median OS was 20.2 vs 15.8 months (HR, 1.14; 95% CI: 0.73–1.79; P=0.5657). Some treatment-emergent adverse events were significantly less common in younger vs older patients, including fatigue (60% vs 69%), cough (20% vs 29%), peripheral edema (17% vs 27%), anemia (18% vs 25%), decreased appetite (13% vs 29%), and thrombocytopenia (16% vs 25%; all P<0.05). Hand–foot syndrome was more common in younger patients (32% vs 24%).Conclusions:Advanced age should not be a deterrent to sunitinib therapy and elderly patients may achieve additional clinical benefit.

DOI: 10.1038/bjc.2013.832

Extracted Key Phrases

7 Figures and Tables

02004006008002014201520162017
Citations per Year

864 Citations

Semantic Scholar estimates that this publication has 864 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Hutson2014EfficacyAS, title={Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma}, author={Thomas E. Hutson and Ronald M. Bukowski and B I Rini and Martin Eric Gore and James Larkin and Robert Alan Figlin and Carlos Henrique Barrios and Bernard J Escudier and Xiyuan Lin and Kolette D Fly and Bridget A Martell and Ewa Matczak and Robert John Motzer}, booktitle={British Journal of Cancer}, year={2014} }